Arsenite resistance in leishmania and possible drug targets

Advances in Experimental Medicine and Biology

Volumn 625, Issue , 2008, Pages 1-8

  Dey, Chinmoy S ^a   Singh, Gaganmeet ^b   Jayanarayan, K G ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TUBULIN; ANILINE DERIVATIVE; ANTIMICROTUBULE AGENT; ANTIMONY; ARSENIC THIOLATE DERIVATIVE; ARSENIC TRIOXIDE; BETA TUBULIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GAMMA TUBULIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE SYNTHASE; GLYCOPROTEIN P; PACLITAXEL; TRIFLURALIN; TUBULIN; UNCLASSIFIED DRUG;

APOPTOSIS; ATOMIC ABSORPTION SPECTROMETRY; DEPOLYMERIZATION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; GENE; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GLUTATHIONE METABOLISM; HUMAN; IC 50; IMPGPA GENE; IN VIVO STUDY; ISOTOPE LABELING; ITPGPA GENE; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIA TARENTOLAE; LEISHMANIASIS; MICROTUBULE ASSEMBLY; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; SPECIES DIFFERENCE; WILD TYPE;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 84934439857     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77570-8_1     Document Type: Review

References (61)

1. http://www.who.int/leishmaniasis.
2. Russo R, Laguna F, Lopez-Velez R et al. Visceral leishmaniasis in those infected with HIV: Clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 2003; 97:99-105.
3. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19:502-508.
4. Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001; 6:899-905.
5. Oullette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: Drugs in clinic, resistance and new developments. Drug Resist Updat 2004; 7:257-66.
6. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol Dis 2003; 2:14.
7. Detke S, Katakura K, Chang KP. DNA amplification in arsenite resistant Leishmania. Exp Cell Res 1989; 180:161-170.
8. Ouellette M, Hettema E, Wust D et al. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. EMBO J 1991; 10:1009-1016.
9. Callahan HL, Beverley SM. Heavy metal resistance: A new role for P-glycoproteins in Leishmania. J Biol Chem 1991; 266:18427-30.
10. Sho-Tone L, Tarn C, Wang CY. Characterization of sequence changes in kinetoplast DNA maxicircles of drug-resistant Leishmania. Mol Biochem Parasitol 1992; 56:197-208.
11. Prasad V, Kaur J, Dey CS. Arsenite-resistant Leishmania donovani promastigotes express an enhanced membrane P-type adenosine triphosphatase activity that is sensitive to verapamil treatment. Parasitol Res 2000; 86:661-664.
12. Beverley SM. Gene amplification in Leishmania. Annu Rev Microbiol 1991; 45:417-44.
13. Ouellette M, Borst P. Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res Microbiol 1991; 142:737-746.
14. Segovia M. Leishmania gene amplification: A mechanism of drug resistance. Ann Trop Med Parasitol 1994; 88:123-30.
15. Schallig HD, Oskam L. Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Trop Med Int Health 2002; 7:641-51.
16. Ouellette M, Papadopoulou B. Mechanism of drug resistance in Leishmania. Parasitol Today 1993; 9:150-153.
17. Grondin K, Papadopoulou B, Ouellette M. Homologous recombination between direct repeats sequences yields P-glycoprotein containing circular amplicons in arsenite resistant Leishmania. Nucleic Acids Res 1993; 21:1895-1901.
18. Detke S, Chaudhuri G, Kink JA et al. DNA amplification in tunicamycin-resistant Leishmania mexicana. Multicopies of a single 63-kilobase supercoiled molecule and their expression. J Biol Chem 1988; 263:3418-3424.
19. Beverley SM, Coderre JA, Santi DV et al. Unstable DNA amplifications in methotrexate-resistant Leishmania consist of extrachromosomal circles which relocalize during stabilization. Cell 1984; 38:431-439.
20. OueUette M, Fase-Fowler F, Borst P. The amplified H circle of methotrexate resistant Leishmania contains a novel P-glycoprotein gene. EMBO J 1990; 9:1027-1033.
21. Callahan HL, Beverley SM. Heavy metal resistance: A new role for P-glycoproteins in Leishmania. J Biol Chem 1991; 266:18427-30.
22. Papadopoulou B, Roy G, Dey S et al. Contribution of the Leishmania P-glycoprotein-related gene ltpgpA to oxyanion resistance. J Biol Chem 1994; 269:11980-6.
23. Dey S, Papadopoulou B, Haimeur A et al. High level resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol 1994; 67:49-57.
24. Grondin K, Haimeur A, Mukhopadhyay R et al. Coamplification of the gamma-glutamylcysteine synthetase gene gshl and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 1997; 6:3057-3065.
25. Singh AK, Liu HY, Lee ST. Atomic absorption spectrophotometric measurement of intracellular arsenite in arsenite-resistant Leishmania. Mol Biochem Parasitol 1994; 66:161-164.
26. Papadopoulou B, Roy G, Dey Set al. Gene disruption of the P-glycoprotein related gene pgpa of Leishmania tarentolae. Biochem Biophys Res Commun 1996; 224:772-778.
27. Dey S, Ouellette M, Lightbody Jet al. An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci USA 1996; 93:2192-2197.
28. Mukhopadhyay R, Dey S, Xu Net al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci USA 1996; 93:10383-10387.
29. Kaur J, Dey CS. Putative P-glycoprotein expression in arsenite-resistant Leishmania donovani down-regulated by verapamil. Biochem Biophys Res Commun 2000; 271:615-619.
30. Lin YC, Hsu JY, Chiang SC et al. Distinct overexpression of cytosolic and mitochondrial tryparedoxin peroxidases results in preferential detoxification of different oxidants in arsenite-resistant Leishmania amazonensis with and without DNA amplification. Mol Biochem Parasitol 2005; 142:66-75.
31. Jayanarayan KG, Dey CS. Microtubules: Dynamics, drug interaction and drug resistance in Leishmania. J Clin Pharm Therapeut 2002; 27:313-320.
32. Werbovetz KA, Brendle JJ, Sackett DL. Purification, characterization, and drug susceptibility of tubulin from Leishmania. Mol Biochem Parasitol 1999; 98:53-65.
33. Croft SL. Recent developments in the chemotherapy of leishmaniasis. Trends Pharmacol Sci 1988; 9:376-381.
34. Seeback T, Hemphill A, Lawson D. The Cytoskeleton of trypanosomes. Parasitol Today 1990; 6:49-52.
35. Prasad V, Kumar SS, Dey CS. Resistance to arsenite modulates levels of alpha-tubulin and sensitivity to paclitaxel in Leishmania donovani. Parasitol Res 2000; 86:838-842.
36. Prasad V, Dey CS. Tubulin is hyperphosphorylated on serine and tyrosine residues in arsenite-resistant Leishmania donovani promastigotes. Parasitol Res 2000; 86:876-880.
37. Jayanarayan KG, Dey CS. Resistance to arsenite modulates expression of beta- and gamma-tubulin and sensitivity to paclitaxel during differentiation of Leishmania donovani. Parasitol Res 2002; 88:754-759.
38. Jayanarayan KG, Dey CS. Altered expression, polymerisation and cellular distribution of alpha-/ beta-tubulins and apoptosis-like cell death in arsenite resistant Leishmania donovani promastigotes. Int J Parasitol 2004; 34:915-925.
39. Dumontet C. Mechanism of action and resistance to tubulin binding agents. Expert Opinion Inves Drugs 2000; 9:779-788.
40. Rodionov V, Nadezhdina E, Boriy G. Centrosomal control of microtubule dynamics. Proc Natl Acad Sci USA 1999; 96:115-120.
41. Margolis RL, Wilson L. Microtubule treadmilling: What goes around comes around. Bioessays 1998; 20:830-836.
42. Little M, Seehaus T. Comparative analyses of tubulin sequences. Comp Biochem Physiol 1988; 90:655-670.
43. Ojima I. A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. J Med Chem 1995; 38:3891-3894.
44. Jayanarayan KG, Dey CS. Altered tubulin dynamics, localization and post-translational modifications in sodium arsenite resistant Leishmania donovani in response to paclitaxel, trifluralirt and a combination of both and induction of apoptosis-like cell death. Parasitology 2005; 131:215-230.
45. Werbovetz KA. Tubulin as an antiprotozoal drug target. Mini Rev Med Chem 2002; 2:519-529.
46. Havens CG, Bryant N, Asher Let al. Cellular effects of leishmanial tubulin inhibitors on Leishmania donovani. Mol Biochem Parasitol 2000; 110:223-36.
47. Wang JC. Cellular roles of DNA topoisomerases: A molecular prospective. Nat Rev Mol Cell Biol 2002; 3:430-440.
48. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as antitumor drug targets. Adv Pharmacol 1991; 21:149-183.
49. Heisig P. Inhibitors of bacterial topoisomerases: Mechanisms of action and resistance and clinical aspects. Planta Med 2001; 67:3-12.
50. Shlomai J. The structure and replication of kinetoplast DNA. Curr Mol Med 2004; 4:623-647.
51. Lee ST, Tam C, Wang CY. Characterization of sequence changes in kinetoplast DNA maxicircles of drug-resistant Leishmania. Mol Biochem Parasitol 1992; 56:197-207.
52. Lee ST, Tarn C, Chang KP. Characterization of the switch of kinetoplast DNA minicircle dominance during development and reversion of drug resistance in Leishmania. Mol Biochem Parasitol 1993; 58:187-203.
53. Lee ST, Liu HY, Lee SP et al. Selection for arsenite resistance causes reversible changes in minicircle composition and kinetoplast organization in Leishmania mexicana. Mol Cell Biol 1994; 14:587-596.
54. Pu QQ, Bezwoda WR. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line. Anticancer Res 2000; 20:2569-22578.
55. Jayanarayan KG, Dey CS. Overexpression and increased DNA topoisomerase II-like enzyme activity in arsenite resistant Leishmania donovani. Microbiol Res 2003; 158:55-58.
56. Singh G, Jayanarayan KG, Dey CS. Novobiocin induces apoptosis-like cell death in topoisomerase II over-expressing arsenite resistant Leishmania donovani. Mol Biochem Parasitol 2005; 141:57-69.
57. Shapiro TA, Englund PT. The structure and replication of kinetoplast DNA. Annu Rev Microbiol 1995; 49:117-143.
58. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99:167-181.
59. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48:3010-3015.
60. Guimond C, Trudel N, Brochu C et al. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res 2003; 31:5886-5896.
61. Drummelsmith J, Brochu V, Girard Iet al. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol Cell Proteomics 2003; 2:146-155.